US Outlets for Evolis, page-3

I'm a believer In the current strategy, taking a step back yes the share price decline has been dismal yet sales are increasing and they are on the right track. Cash flow positive is just around the corner and once we are there they can then put profits into the clinical trials without going back to investors for more cash.

Market is definitely not attributing any good will into CDY so it will be purely based on profitability and positive clinical trials.

Would be nice to see the board spruk the stock with some bigger fund managers to get some movement upwards.